Illumina, Inc. Share Price and Company Fundamentals
Last traded: Last Wednesday at 8:00 PM
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
|Industry / Sector||Diagnostics & Research / Healthcare|
|Full time employees||7800|
|Mailing address||5200 Illumina Way San Diego CA 92122 United States|
|Phone / Fax||858 202 4500 / 858 202 4545|
Illumina, Inc. does not pay dividends.
As of May 2021, following are the company executives and directors listed on Illumina, Inc..
|Mr. Francis A. deSouza||CEO & Director||49|
|Mr. Sam A. Samad||Chief Financial Officer||50||716.04k|
|Dr. Alexander Aravanis M.D., Ph.D.||Chief Technology Officer||44||416.48k|
|Ms. Susan H. Tousi||Chief Product Officer||51||655.31k|
|Mr. Robert P. Ragusa||Chief Operations Officer||60|
|Mr. Jose A. Torres Jr.||Chief Accounting Officer & VP||45|
|Mr. Steve Phillpott||Sr. VP & Chief Information Officer|
|Ms. Juliet Cunningham||VP of Investor Relations|
|Mr. Charles E. Dadswell||Sr. VP, Gen. Counsel & Sec.||61|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Illumina, Inc. is 54.43B and its enterprise value is 53.49B. The enterprise value to revenue ratio of ILMN is 15.40.
The ILMN's stocks Beta value is 0.97 making it 3% less volatile compared to NASDAQ market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Illumina, Inc. (NASDAQ:ILMN) Frequently Asked Questions
1. What is Illumina, Inc.'s Stock Symbol?
Illumina, Inc. trades on NASDAQ under the ticker symbol "ILMN".
2. What is Illumina, Inc.'s stock price today?
One share of ILMN stock can currently be purchased for approximately $372.84.
3. How can I contact Illumina, Inc.?
Illumina, Inc.'s mailing address is 5200 Illumina Way San Diego CA 92122 United States. The company can be reached via phone at 858 202 4500.
4. What is Illumina, Inc.'s official website?
The official website of Illumina, Inc. is http://www.illumina.com.